USA - February 18 2021
The Federal Circuit considered its 35 U.S.C. § 112 enablement case law and found that “the enablement inquiry for claims that include functional…
Matthew Weiss
USA - January 28 2021
The Federal Circuit has spoken. In a per curiam opinion, it denied Valeant’s petition for rehearing by the panel and rehearing en banc. A case…
Jordan Engelhardt, Matthew Weiss
USA - January 11 2021
Last week, Mylan filed a brief in opposition to Valeant’s petition for rehearing en banc in Valeant Pharms. N. Am. LLC v. Mylan Pharms. Inc., No…
Jordan Engelhardt, Matthew Weiss
USA - December 14 2020
Earlier this month, Valeant Pharmaceuticals North America LLC (“Valeant”) filed a petition for rehearing en banc in Valeant Pharms. N. Am. LLC v…
Jordan Engelhardt, Matthew Weiss
USA - November 19 2020
On November 5, 2020, in Valeant Pharms. N. Am. LLC v. Mylan Pharms. Inc., No. 2019-2402, the Federal Circuit held that venue in Hatch-Waxman cases…
Jordan Engelhardt, Aron Fischer, William F. Cavanaugh, Jr., Barbara L. Mullin, Matthew Weiss